No one ever climbed the industry ladder without getting some help along the way. And for women, including many of the accomplished top performers in this group, that can be especially important. Maybe it was an encouraging nudge for a bright young scientist or a willing mentor for a rising company player--but virtually everyone in this year's group of top women in biotech benefited from a higher-up's helping hand.
Now, these women are re-gifting that upward boost to the next generation of leaders. Some are actively involved in nonprofit groups aiming to inspire women in business. Others single out promising younger women who might benefit from their guidance and experienced counsel.
This year's Class of 2013 includes entrepreneurs running biotechs, raising cash and advancing new drugs in the clinic. Read the full report >>
In a way, the coming year isn't a big one for patent expirations. The total amount of sales jeopardized by patent expirations is $34 billion. That's more than the $28 billion this year, but far less than the $55 billion that hit in 2012. As for 2015? Forget about it. That year, products worth $66 billion will lose IP protection.
Plus, the drugs facing new competition won't all take a big hit in 2014. In fact, EvaluatePharma figures that the products newly open to generic competition will only lose $13 billion off their previous totals.
But if you're one of the companies looking at sudden exposure to would-be copycats, 2014 might be a very big year indeed. Check out the report >>
The Hatch-Waxman Act shook up the generic drugs business in 1984, and almost 30 years later, it's safe to say the law had its desired effect. About 84% of the 4 billion prescriptions written each year are for generic drugs, saving patients and government programs billions of dollars a year. In other words, generic drugs are big business. And with a slew of blockbuster brands now off patent, it's a big business with growing pains.
As companies bulked up to take on copies of the world's best-selling drugs, a wave of mergers has swept the industry. Many credit Actavis CEO Paul Bisaro with starting that trend; then the Watson CEO, his 2012 takeover of Actavis sent a clear message of "go big or go home" reverberating throughout the generics business. Actavis hasn't stopped scouting for deals, and many of its peers have followed suit.
Peruse the Top 10 to find out how these trends and market forces are shaping the industry's biggest players--and vice versa. Read the report >>
Have something to say? Join other pharma
executives on FiercePharma's LinkedIn group.
POPULAR COMMENT THREADS
When the FDA finds deep flaws at a manufacturing plant, it questions practices at all other facilities in the network. Hospira found this out in 2010 when a second warning letter in 8 months prompted the FDA to ask it to do a global review, and Wockhardt has now been given a similar regulatory to-do list.
The past few weeks have seen a spate of pharma manufacturing cuts, with Actavis, Merck and Pfizer all whacking jobs. And Pfizer has continued its busy end to 2013 by revealing it is to close a packaging plant in Ireland, laying off 150 workers in the process.
When Boehringer Ingelheim began closing its Ben Venue site, it justified the decision by describing a grim future for the plant, with operating losses of $700 million forecast over the next 5 years. Now it hopes someone can look past the losses and troubled quality control record to see a business worth buying.
For any company entering the immunotherapy field, manufacturing and logistics are huge challenges. At newly formed Juno Therapeutics, they have a plan to overcome these obstacles--find a CEO who has done it before and back him with $120 million.
In September, a federal judge set back drugmakers' efforts to avoid picking up the tab for drug-disposal schemes when he ruled in favor of Alameda County. Having failed in California, the lobbying juggernaut is trying to stop biopharma-funded disposal schemes spreading up the coast to Seattle.
CMO Patheon is investing in a U.K. site to increase capacity and add capabilities, including automated capsule filling. The expansion comes as Patheon prepares to merge with DSM's pharma business under the ownership of JLL Partners.
From Our Sister Sites
The FDA has stamped its approval on sofosbuvir for hepatitis C, perhaps one of the most anticipated new drugs of the year. Gilead's therapy, which will be marketed as Sovaldi, will open the door to a new generation of treatments that don't require interferon--freeing patients from an arduous regimen tied to a host of nasty side effects.
The European Medicines Agency has decided to look again at the clotting risks of Ariad Pharmaceuticals' troubled cancer drug Iclusig.